- Epcoritamab monotherapy in Arm 2A showed a 57% overall response rate and 52% complete response rate in first-line RT patients.
- In Arm 2B, epcoritamab combined with lenalidomide achieved an 82% overall response rate in previously treated RT patients.
- Arm 2C results showed a 77% overall response rate for epcoritamab combined with R-CHOP in untreated RT patients.
- Cytokine release syndrome was common but mostly low grade and resolved quickly across all trial arms.
Monotherapy Results
In the EPCORE® CLL-1 trial, Arm 2A evaluated epcoritamab as a monotherapy for Richter Transformation (RT) patients. Among first-line RT patients, the overall response rate (ORR) was 57%, with a complete response (CR) rate of 52%. For those in second- or later-line settings, the ORR was 38% and the CR rate was 29%.
Combination with Lenalidomide
Arm 2B assessed epcoritamab combined with lenalidomide in previously treated RT patients. The ORR was 82%, and the CR rate was 73%. The median overall survival (OS) at nine months was not reached, indicating promising efficacy.
Combination with R-CHOP
In Arm 2C, epcoritamab was combined with R-CHOP for untreated RT patients. The ORR was 77%, and the CR rate was 63%. The median OS was 16.4 months, and the median progression-free survival (PFS) was 16.0 months.
Safety Profile
Cytokine release syndrome (CRS) was common across all trial arms but mostly low grade, resolving quickly in most cases. Immune effector cell-associated neurotoxicity syndrome (ICANS) and clinical tumor lysis syndrome (CTLS) were also observed but were generally manageable.
